Pulmonary Disease, Chronic Obstructive — Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
Citation(s)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD